Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme

Drug Metabolism and Disposition

Volumn 35, Issue 9, 2007, Pages 1657-1663

  Kassahun, Kelem ^a   McIntosh, Ian ^a   Cui, Donghui ^a   Hreniuk, David ^b   Merschman, Shelia ^a   Lasseter, Kenneth ^c   Azrolan, Neal ^b   Iwamoto, Marian ^b   Wagner, John A ^b   Wenning, Larissa A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SFBC International ^*

^c SFBC International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CARBON 14; COMPLEMENTARY DNA; GLUCURONOSYLTRANSFERASE 1A1; INTEGRASE; INTEGRASE INHIBITOR; PROTEIN M2; RALTEGRAVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DRUG URINE LEVEL; FECES ANALYSIS; GLUCURONIDATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; TANDEM MASS SPECTROMETRY; URINALYSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1; RATTUS;

EID: 34548065793     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.016196     Document Type: Article

References (16)

1. Asante-Appiah E and Skalka AM (1999) HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res 52:351-369.
2. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Elferink RPJO, Roy Chowdhury J, Roy Chowdhury N, and Jansen PLM (1994) Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269:17960-17964.
3. Esposito D and Craigie R (1999) HIV integrase structure and function. Adv Virus Res 52:319-333.
4. Hop ECA, Wang Z, Chen Q, and Kwei G (1998) Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901-903.
5. th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland, November 2006. Abstract P299.
6. th Annual ICAAC Meeting. San Francisco, CA, September 2006. Abstract A-373.
7. Lin JH and Wong BK (2002) Complexities of glucuronidation affecting in vitro-in vivo extrapolation. Curr Drug Metab 3:623-646.
8. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, et al. (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347:375-394.
9. Markowitz M, Morales-Ramirez O, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, et al. (2006) Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 43:509-515.
10. Miners JO, Knights KM, Houston BJ, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
11. th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sidney, Australia, July 2007. Abstract 1985.
12. th Annual ICAAC Meeting. San Francisco, CA, September 2006. Abstract A-376.
13. Richman DD (2001) HIV chemotherapy. Nature 410:995-1001.
14. th Annual ICAAC Meeting. San Francisco, CA, September 2006. Abstract A-375.
15. th Annual ICAAC Meeting. San Francisco, CA, September 2006. Abstract A-374.
16. i/AUC) ratios. Drug Metab Dispos 32:1201-1208.